Table 2.
Changes in secondary efficacy variables during treatment with prolonged-release oxycodone/naloxone (OXN-PR)
| Variable | Baseline | T7 | T15 | T45 | P-value |
|---|---|---|---|---|---|
| Rescue analgesics | 17 (32.1) | 16 (30.2) | 14 (26.4) | 12 (22.6) | 0.24a |
| Adjuvants | 18 (34.0) | 14 (26.4) | 15 (28.3) | 13 (24.5) | 0.34a |
| NPI | 25.5±27.3 | 20.6±23.0 | 11.6±11.3c | 8.8±9.0 | <0.0001b |
| BFI | 25.6±19.7 | 24.5±17.9 | 19.7±16.2c | 18.1±16.9 | <0.0001b |
| Laxatives | 21 (39.6) | 30 (56.6)c | 32 (60.4) | 31 (58.5) | 0.047a |
Notes: All values are expressed as mean ± standard deviation or n (%). T45 versus baseline.
a
Chi-square for trend;
b
analysis of variance;
c
P<0.05 versus previous observation.
Abbreviations: BFI, Bowel Function Index; NPI, Neuropsychiatric Inventory; T7, T15, and T45, respectively, 7-, 15-, and 45-day treatment with OXN-PR.